![]() Inhibitors of dipeptidyl peptidase (DPP)-4 have been developed based on the gut-derived glucagon-like peptide-1, one of specific antidiabetic hormones because it promotes insulin release and suppresses glucagon secretion ( Lambeir et al., 2003 Yin et al., 2022). Insulin, a peptide hormone and growth factor, which is critical in patients with diabetes because it promotes both the healing of injured skin by stimulating the signal of proliferation and migration and growth factor release through the stimulation of endothelial cells, fibroblasts, and keratinocytes ( Gurtner et al., 2008 Brem and Tomic-Canic, 2007 Wertheimer et al., 2001). Hyperglycemia in patients with diabetes has been found to disrupt the balance of pressure-induced vasodilation due to the dysfunction of endothelial cells, to interfere with the processes of re-epithelialization as a result of protein synthesis, cell migration and proliferation ( Lima et al., 2017), and to increase free radical damage that is caused by reducing antioxidant activity ( Sedighi et al., 2014). Diabetic wounds leading to lower extremity amputation are one of the most common adverse outcomes associated with diabetes mellitus, and impairment of their healing leads to high mortality ( Armstrong et al., 2020). Slow wound repair in diabetes is a serious adverse event that often results in loss of a limb or disability ( Menke et al., 2015). Core-shell insulin/vildagliptin-loaded nanofibers extend the drug delivery of insulin and vildagliptin and accelerate the repair of wounds associated with diabetes.ĭiabetes mellitus is regarded as an important health issue that affects millions of people, predisposing them toward macro-and micro-vascular complications ( Misra et al., 2019). The insulin/vildagliptin-loaded core-shell nanofibers improved endothelial progenitor cells migration in vitro (762 ± 77 cells/mm 2 vs. 283% ± 24%, p = 0.003) of the insulin/vildagliptin core-shell nanofibrous membranes remarkably exceeded those of a control group. Results and Discussion: Nanofibrous core-shell scaffolds slowly released effective vildagliptin and insulin over 2 weeks in vitro migration assay and in vivo wound-healing models. Methods: To fabricate core-shell nanofibrous membranes, vildagliptin mixture with PLGA, and insulin solution were pumped via separate pumps into two differently sized capillary tubes that were coaxially electrospun. Nanofibrous insulin/vildagliptin core-shell biodegradable poly (lactic-co-glycolic acid) (PLGA) scaffolds to prolong the effective drug delivery of vildagliptin and insulin for the repair of diabetic wounds were prepared. An advanced and encouraging vehicle is wanted to enhance clinically applicable diabetic wound care. Introduction: Slow wound repair in diabetes is a serious adverse event that often results in loss of a limb or disability. ![]()
0 Comments
Leave a Reply. |